Author

Guillermo Antonio Llamas Esperón

Observed names: Guillermo Antonio Llamas Esperon, Guillermo Esperón

Observed institution: Technical University of Munich

OpenAlex ID: A5114097288

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

2019 · Kausik K Ray, Helen M Colhoun, et al. · The Lancet Diabetes & Endocrinology · 315

The Changing Landscape for Stroke Prevention in AF

2017 · Menno V. Huisman, Kenneth J. Rothman, et al. · Journal of the American College of Cardiology · 280

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

2021 · Gregory G. Schwartz, Gregory G. Schwartz, et al. · Journal of the American College of Cardiology · 148

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

2022 · Emil Hagström, P. Gabriel Steg, et al. · Circulation · 118

Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE

2020 · Jeffrey I. Weitz, Sylvia Haas, et al. · Journal of Thrombosis and Thrombolysis · 113

Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD‐VTE patients

2019 · Sylvia Haas, Walter Ageno, et al. · Journal of Thrombosis and Haemostasis · 41

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

2021 · Gregory G. Schwartz, Michael Szarek, et al. · Diabetes Care · 40

36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE

2022 · Alexander G.G. Turpie, Alfredo E. Farjat, et al. · Thrombosis Research · 27

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES

2025 · P. Gabriel Steg, Michael Szarek, et al. · Circulation · 26

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

2024 · Shaun G Goodman, Philippe Gabriel Steg, et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 25

Incidence and predictors of post-thrombotic syndrome in patients with proximal DVT in a real-world setting: findings from the GARFIELD-VTE registry

2023 · Paolo Prandoni, Sylvia Haas, et al. · Journal of Thrombosis and Thrombolysis · 17

GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

2022 · Sylvia Haas, John A. Camm, et al. · Clinical Research in Cardiology · 12

Works count: 12

Citation count: 1,161

H-index: 12

I10-index: 12